The role of follow-up CA15-3 in prognosis of breast cancer

Background: The purpose of this study is to confirm the usefulness of Cancer Antigen 15-3 (CA15-3) follow-up. We determine whether the change in the values of breast cancer tumor marker CA15-3 before and after treatment is useful as a prognostic factor for disease progression. Methods: We conducted a retrospective cohort study of female patients who were newly diagnosed with primary breast cancer. CA15-3 levels were checked 1 month preoperatively and at 1 year (Y) postoperatively. Disease-free survival and metastasis-free survival were analyzed according to CA15-3 levels and changes. Results: We analyzed the prognostic effect of the CA15-3 levels. Lymph node metastasis and postoperative 1Y CA15-3 levels were significant factors of disease-free survival. And elevated postoperative 1Y CA15-3 level was the only significant prognostic factor for metastasis-free survival. The study groups were classified into four subgroups according to the changes in CA15-3 level (preoperative–postoperative 1Y CA15-3). The normal-normal group showed the best disease-free and metastasis-free survival, while the elevated-elevated group showed the worst survival. Conclusions: We found that persistently high CA15-3 levels after the initial treatment might be a significant prognostic factors of worse breast cancer prognosis.

Breast cancer; Tumor marker; CA15-3

[1] Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research. 2007; 13: 2329–2334.

[2] Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031. Journal of Clinical Oncology. 2011; 29: 2342–2349.

[3] Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology. 2008; 26: 1275–1281.

[4] Sandri MT, Salvatici M, Botteri E, Passerini R, Zorzino L, Rotmensz N, et al. Prognostic role of CA15.3 in 7942 patients with operable breast cancer. Breast Cancer Research and Treatment. 2012; 132: 317–326.

[5] Hayes DF. Markers of increased risk for failure of adjuvant therapies. The Breast. 2003; 12: 543–549.

[6] Li G, Hu J, Hu G. Biomarker studies in early detection and prognosis of breast cancer. Advances in Experimental Medicine and Biology. 2017; 7: 27–39.

[7] Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, et al.; St Gallen Consensus Conference Panelists 2023. Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the primary therapy of individuals with early breast cancer 2023. Annals of Oncology. 2023; 34: 970–986.

[8] Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2024; 22: 331–357.

[9] Gendler SJ, Spicer AP, Lalani EN, Duhig T, Peat N, Burchell J, et al. Structure and biology of a carcinoma-associated mucin, MUC1. American Review of Respiratory Disease. 1991; 144: S42–S47.

[10] Hayes DF, Mesa-Tejada R, Papsidero LD, Croghan GA, Korzun AH, Norton L, et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a cancer and leukemia group B study. Journal of Clinical Oncology. 1991; 9: 1113–1123.

[11] Park S, Ahn HK, Park LC, Hwang DW, Ji JH, Maeng CH, et al. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer. Oncology. 2012; 82: 180–187.

[12] Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Annals of Oncology. 2012; 23: 338–345.

[13] Li H, Chen K, Su F, Song E, Gong C. Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal a breast cancer. Journal of Surgical Research. 2014; 189: 48–56.

[14] Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. PLOS ONE. 2015; 10: e0133830.

[15] Kos T, Aksoy S, Sendur MA, Arik Z, Civelek B, Kandemir N, et al. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes. Journal of BUON. 2013; 18: 608–613.

[16] Moazzezy N, Farahany TZ, Oloomi M, Bouzari S. Relationship between preoperative serum CA 15-3 and CEA levels and clinicopathological parameters in breast cancer. Asian Pacific Journal of Cancer Prevention. 2014; 15: 1685–1688.

[17] Araz M, Beypinar I, Kazan S, Inci F, Celiker M, Uysal M. Are preoperative serum CA15-3 levels different in breast cancer subgroups? Current Problems in Cancer. 2019; 43: 115–122.

[18] Zhang J, Wei Q, Dong D, Ren L. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. Clinica Chimica Acta. 2021; 523: 19–25.

[19] International Breast Cancer Study Group (IBCSG); Castiglione-Gertsch M, O’Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. Journal of the National Cancer Institute. 2003; 95: 1833–1846.

[20] International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. Journal of the National Cancer Institute. 2002; 94: 1054–1065.

[21] Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, et al. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of Oncology. 2007; 18: 701–708.

[22] Li J, Liu L, Feng Z, Wang X, Huang Y, Dai H, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer. 2020; 27: 621–630.

[23] Nisman B, Maimon O, Allweis T, Kadouri L, Maly B, Hamburger T, et al. The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer. Anticancer Research. 2013; 33: 293–299.